89 completed, 55 recruiting, 47 active not recruiting, 26 unknown. 148 Phase 2, 69 Phase 1, 69 Phase 3, 11 Not applicable, 3 Phase 4.
Follow Platinum: new trials by email Literature Review of Platinum trials Research Report on Platinum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 1 | Suspended | University of Maryland, Baltimore | 50 | 2027-01-30 | 2026-09-14 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy Third-generation EGFR tyrosine kinase inhibitor, Platinum plus pemetrexed chemotherapy, Pemetrexed maintenance therapy - EGFR-mutant Non-small Cell Lung Cancer, SBRT | Phase 2 | Not yet recruiting | Fudan University | 374 | 2026-10-01 | 2026-09-16 |
| Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Carboplatin - Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 108 | 2026-09-01 | 2026-10-05 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer Biospecimen Collection, Carboplatin, Cemiplimab - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 180 | 2026-04-24 | 2026-10-14 |
| A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer BMS-986504, Ipilimumab, Nivolumab - Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-04-07 | 2026-09-16 |
| JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer JSKN033, Platinum, Bevacizumab - Cervical Cancer | Phase 2 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 78 | 2026-04-01 | 2026-03-27 |
| QLS5132 Combination Therapy in Advanced Solid Tumors QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab - Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 626 | 2026-04-01 | 2026-03-06 |
| Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer primary RPLND for low-stage metasatatic seminoma, 3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP) - Testicular Cancer, Seminoma | Not applicable | Recruiting | Sahlgrenska University Hospital | 160 | 2026-03-19 | 2026-03-27 |
| Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda Hypofractionated Radiation Therapy, Conventional Fractionated Radiotherapy, Cisplatin - Cervical Cancer, Cervix Cancer | Phase 2 | Recruiting | Uganda Cancer Institute | 278 | 2026-03-11 | 2026-03-27 |
| Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors Audiometric Test, Cisplatin, Computed Tomography - Hearing Loss, Metastatic Malignant Germ Cell Tumor | Phase 1 | Recruiting | City of Hope Medical Center | 44 | 2026-02-19 | 2026-04-17 |
| PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC QL1706 (bispecific antibody targeting PD-1 and CLTA-4) - Lung Adenocarcinoma | Phase 2 | Not yet recruiting | Guangdong Association of Clinical Trials | 61 | 2026-01-31 | 2026-02-17 |
| Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction Liposome Irinotecan, Platinum, Anlotinib - Small Cell Lung Cancer | Phase 2 | Not yet recruiting | China Medical University, China | 31 | 2026-01-25 | 2026-01-29 |
| Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors QLC5513 IV infusion, QL1706, IV infusion, platinum, IV infusion - Metastatic Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 290 | 2025-12-30 | 2025-12-09 |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence Biopsy Procedure, Biospecimen Collection, Cisplatin - Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Enrolling by invitation | Mayo Clinic | 16 | 2025-12-03 | 2026-07-01 |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer Biospecimen Collection, Carboplatin, Cisplatin - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-12-02 | 2026-10-05 |
Showing 20 of 273. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (35) · Squamous Cell Carcinoma of Head and Neck (22) · Lung Neoplasms (19) · Uterine Cervical Neoplasms (19) · Small Cell Lung Carcinoma (16) · Oropharyngeal Neoplasms (14) · Ovarian Neoplasms (12) · Carcinoma (10) · Cholangiocarcinoma (10) · Fallopian Tube Neoplasms (9) · Laryngeal Neoplasms (9) · Mouth Neoplasms (9) · Stomach Neoplasms (9) · Urinary Bladder Neoplasms (9) · Hypopharyngeal Neoplasms (8)
National Cancer Institute (NCI) (75) · Children's Oncology Group (19) · M.D. Anderson Cancer Center (15) · Mayo Clinic (12) · ECOG-ACRIN Cancer Research Group (11) · Gynecologic Oncology Group (6) · NRG Oncology (6) · GOG Foundation (5) · University of Washington (5) · City of Hope Medical Center (4) · Eastern Cooperative Oncology Group (4) · Fudan University (4) · Jonsson Comprehensive Cancer Center (4) · Roswell Park Cancer Institute (4) · Georgetown University (3)
United States (194) · China (50) · Canada (48) · Australia (24) · Puerto Rico (21) · New Zealand (12) · Japan (7) · Switzerland (7) · France (6) · Hong Kong (5) · Israel (4) · Italy (4) · Poland (4) · Saudi Arabia (4) · Singapore (4)
Jyoti S Mayadev (3) · Nabil F Saba (3) · Anne S Tsao (2) · Brigette B Ma (2) · Carlos Rodriguez-Galindo (2) · Jing Zeng (2) · Monika Joshi (2) · Mustafa Raoof, MD (2) · Parminder Singh (2) · Paul M Harari (2) · Robert Ferris (2) · Sara M Federico (2) · Sarah E Leary (2) · Tina Cascone (2) · Xiuning Le (2)
PMID 34028986, PMID 18784101, PMID 20049927, PMID 20335368, PMID 20458043, PMID 22178121, PMID 22967997, PMID 23265711, PMID 23293700, PMID 23822453, PMID 24164605, PMID 24552320, PMID 24821881, PMID 24856171, PMID 25151979, PMID 25311218, PMID 25421877, PMID 25638326, PMID 25732163, PMID 25847373, PMID 26705063, PMID 27569442, PMID 27619516, PMID 27998970, PMID 28756902, PMID 29129443, PMID 29217088, PMID 29223478, PMID 29296710, PMID 29868473, PMID 30332335, PMID 30523756, PMID 30975630, PMID 30998813, PMID 31002578, PMID 31189035, PMID 31200823, PMID 31383985, PMID 31386610, PMID 31401903, PMID 31454045, PMID 31553639, PMID 31605794, PMID 31618129, PMID 31657981, PMID 31681600, PMID 31702432, PMID 31708167, PMID 31871115, PMID 31912685
U10CA180868 (29), U10CA180820 (24), U10CA180886 (22), U10CA027469 (14), U10CA098543 (14), U10CA021115 (12), U10CA180888 (8), U10CA021661 (7), U10CA180821 (5), P30CA015083 (4), U10CA031946 (4), UM1CA186709 (4), UM1CA186717 (4), P30CA008748 (3), P30CA033572 (3)